French non-profit bets on Duchenne gene therapy that comes in lower dose than Elevidysnews2025-10-10T13:57:21+00:00October 10th, 2025|Endpoints News|
Altos Labs is testing anti-aging therapies in organs kept alive outside the bodynews2025-10-09T19:55:46+00:00October 9th, 2025|Endpoints News|
Mammoth Biosciences plans first trial of triglyceride-lowering gene editing therapynews2025-10-09T13:30:56+00:00October 9th, 2025|Endpoints News|
Finnish researchers report success in mid-stage study of heart disease gene therapynews2025-10-09T10:33:04+00:00October 9th, 2025|Endpoints News|
Updated: Novo Nordisk to buy MASH player Akero for $4.7B upfrontnews2025-10-09T10:23:59+00:00October 9th, 2025|Endpoints News|
In the Lab: How Amgen sees AI changing pharma R&Dnews2025-10-08T14:00:50+00:00October 8th, 2025|Endpoints News|
Dimerix says observational analysis could back speedier path to market for rare kidney disease drugnews2025-10-08T11:09:39+00:00October 8th, 2025|Endpoints News|
Sanofi and radioligand partner Orano Med report mid-stage win in rare tumornews2025-10-08T10:36:44+00:00October 8th, 2025|Endpoints News|
Biomea shares early Phase 2 diabetes data from repurposed cancer candidatenews2025-10-07T11:09:43+00:00October 7th, 2025|Endpoints News|
AeroRx closes $21M Series A in bid to capitalize on COPD momentumnews2025-10-07T11:00:17+00:00October 7th, 2025|Endpoints News|
